Surgery Partners (NASDAQ:SGRY) Price Target Lowered to $14.00 at Barclays

Surgery Partners (NASDAQ:SGRY) had its target price reduced by Barclays from $18.00 to $14.00 in a research report sent to investors on Tuesday,Benzinga reports. They currently have an equal weight rating on the stock.

A number of other analysts have also weighed in on the stock. JPMorgan Chase & Co. reduced their price target on shares of Surgery Partners from $27.00 to $20.00 and set a “neutral” rating for the company in a research note on Monday, November 24th. Weiss Ratings reissued a “sell (e+)” rating on shares of Surgery Partners in a report on Monday, December 29th. UBS Group cut their target price on Surgery Partners from $34.00 to $29.00 and set a “buy” rating for the company in a research report on Thursday, November 13th. Mizuho decreased their price target on Surgery Partners from $22.00 to $19.00 and set an “outperform” rating for the company in a research note on Thursday, December 18th. Finally, Benchmark dropped their price objective on Surgery Partners from $35.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, November 11th. Seven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Surgery Partners currently has an average rating of “Moderate Buy” and a consensus price target of $27.00.

Surgery Partners Trading Down 12.3%

NASDAQ:SGRY opened at $13.92 on Tuesday. The stock has a market cap of $1.80 billion, a price-to-earnings ratio of -22.45 and a beta of 1.95. The company has a debt-to-equity ratio of 1.10, a quick ratio of 1.72 and a current ratio of 1.88. Surgery Partners has a 1 year low of $12.25 and a 1 year high of $24.64. The business has a fifty day moving average of $15.32 and a 200-day moving average of $18.27.

Surgery Partners (NASDAQ:SGRY) last issued its quarterly earnings data on Monday, March 2nd. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.19). The company had revenue of $885.00 million for the quarter, compared to the consensus estimate of $866.54 million. Surgery Partners had a negative net margin of 2.35% and a positive return on equity of 1.28%. Surgery Partners’s revenue for the quarter was up 2.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.44 earnings per share. Equities analysts predict that Surgery Partners will post 0.67 earnings per share for the current year.

Surgery Partners declared that its board has initiated a stock buyback program on Thursday, February 26th that allows the company to repurchase $200.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 9.7% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

Institutional Investors Weigh In On Surgery Partners

Large investors have recently modified their holdings of the stock. Alpine Global Management LLC acquired a new position in shares of Surgery Partners in the 4th quarter worth $175,000. Empowered Funds LLC boosted its position in shares of Surgery Partners by 1,340.9% in the 4th quarter. Empowered Funds LLC now owns 161,419 shares of the company’s stock valued at $2,494,000 after purchasing an additional 150,216 shares during the period. One68 Global Capital LLC purchased a new position in Surgery Partners in the 4th quarter worth about $371,000. Man Group plc purchased a new position in Surgery Partners in the 4th quarter worth about $5,080,000. Finally, Inspire Investing LLC raised its holdings in Surgery Partners by 45.4% during the 4th quarter. Inspire Investing LLC now owns 30,073 shares of the company’s stock worth $465,000 after buying an additional 9,384 shares during the period.

Key Headlines Impacting Surgery Partners

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Announced a share repurchase program, which can support the stock by returning capital and offsetting dilution. Share repurchase program
• Positive Sentiment: Revenue beat: Q4 revenue was $885.0M vs. ~$866.5M consensus, and revenue was up ~2.4% year‑over‑year, showing underlying demand resilience in the business. Q4 revenue beat
• Neutral Sentiment: Q4 earnings call transcript published — useful for detail on margins, volumes, and management commentary for modeling but does not itself move fundamentals. Earnings call transcript
• Negative Sentiment: Earnings miss: Q4 EPS was $0.12 vs. consensus ~$0.31 (and vs. $0.44 a year ago), a substantial shortfall that hit investor confidence. Earnings miss
• Negative Sentiment: Weaker FY‑2026 guidance: management set revenue roughly in a $3.4B–$3.5B range vs. consensus near $3.5B and left EPS guidance unclear/limited, signaling slower growth or margin pressures. That guidance was a primary cause of the selloff. Guidance and outlook
• Negative Sentiment: Analyst reaction: Barclays cut its price target to $14 and moved to an “equal weight” stance, reducing upside expectations and likely keeping additional selling pressure on the stock. Barclays price target cut
• Negative Sentiment: Market reaction: multiple reports show the stock fell sharply on the earnings/guidance news (heavy volume), reflecting investor disappointment and increased near‑term downside risk. Market reaction

About Surgery Partners

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.